Here's Wouldn't Touch Tilray: A Cautious Investor Guide
Tilray’s pivot to CBD and alcohol sparks questions about profitability and risk. This guide cuts through the hype, of...
Understand why methodology matters in investing and how it affects risk assessment, accuracy, and investment outcomes.
21,903 articlesTilray’s pivot to CBD and alcohol sparks questions about profitability and risk. This guide cuts through the hype, of...
Amazon has faced headwinds and briefly dipped below $200. This guide explains how to evaluate a dip, set targets, and...
When a cybersecurity giant bets $25 billion on a single platform, investors should understand the why, the potential ...
Curious about SoundHound AI's future? This in-depth guide lays out five-year scenarios, key drivers, and concrete tip...
A fund exited its Centerra Gold stake after a 150% rally, triggering talks of profit-taking and risk management. This...
A hedge fund made a sizable Ultragenyx purchase as the stock slipped about 30% over the prior year. This article brea...
When a popular cybersecurity name sells off, investors wonder if it’s a dip worth buying. This guide looks at fundame...
CRISPR Therapeutics stock has zigzagged all year, driven by pipeline milestones, regulatory updates, and funding need...
Investors woke up to a surge in Qualcomm stock after the company outlined bold AI-backed growth targets. This article...
Berkshire Hathaway under Greg Abel signals a sharper eye for AI champions. Could Alphabet be the catalyst, with Nvidi...
A blockbuster TSMC update is reshaping the AI chip market. Here are three stocks I’m buying after Taiwan’s announceme...
Snap once soared to a record high, but the stock now sits well below that peak. This article breaks down the recovery...